Press release summary
Lanterne Dx has completed its merger with Flagship Biosciences, combining a CAP- and CLIA-accredited histopathology laboratory with computational pathology, image analysis and regulatory-support capabilities. The combined organization will operate under the Lanterne Dx name.
Lanterneโs laboratory services cover antibody development, optimization and validation, as well as immunohistochemistry, immunofluorescence, multiplexing, in situ hybridization, fluorescence in situ hybridization, pathology review and data analysis. Flagship contributes artificial-intelligence-assisted image analysis and digital tissue-analysis expertise. The companies said the integrated operation will support pharmaceutical and biotechnology programs from discovery and translational research through clinical development. Financial terms were not disclosed.
Why it matters for laboratories
Combining wet-lab histopathology with computational analysis can reduce handoffs between tissue processing, biomarker validation, slide interpretation and quantitative image review. A single workflow may also make method transfer, data traceability and regulatory documentation easier to coordinate across a development program. The announcement establishes broader capabilities, but it does not provide performance comparisons, turnaround-time improvements or integration milestones, so laboratories should evaluate those operational details before selecting the combined service.
Original source: Lanterne Dxโs Oct. 5, 2026, announcement.






Leave a Reply